Actinogen boosts trial with Cambridge Cognition’s digital suite

Partnership aims to advance Alzheimer’s research with innovative tools

Cambridge Cognition Holdings plc has expanded its partnership with Actinogen Medical Limited for the phase 2b/3 XanaMIA Alzheimer’s disease trial.

Building on the successful integration of Cambridge Cognition’s digital tools during the first phase of this study, Actinogen will continue to use the company’s validated tools for more precise clinical measurements.

With dementia affecting 47 million people worldwide, Cambridge Cognition is proud to support innovative Alzheimer’s research.

Actinogen is developing a novel therapy to control elevated brain cortisol levels and slow or halt disease progression.

The phase 2b/3 trial includes 220 patients with mild or moderate dementia due to Alzheimer’s disease and elevated plasma biomarker, pTau181.

Patients will receive emestedastat (Xanamem) 10 mg or a placebo, once daily, over a 36-week period.

The trial’s primary endpoint is the Clinical Dementia Rating scale – Sum of Boxes (CDR-SB), supported by Cambridge Cognition. Secondary cognitive endpoints include Cambridge Cognition’s CANTAB Attention and working memory battery and the automated quality assurance solution, AQUA.

Rob Baker, Joint Managing Director and Chief Operating Officer at Cambridge Cognition, said, “We are proud to deepen our collaboration with Actinogen in their important work in Alzheimer’s research.” He added that their integrated platform optimises clinical assessments while upholding exceptional data quality standards.

Dr Steven Gourlay, Actinogen’s CEO and MD, commented, “Actinogen’s commitment to advancing Alzheimer’s research demands robust and reliable data collection.” He noted that Cambridge Cognition’s comprehensive solution strengthens confidence in data integrity for the XanaMIA trial.

Cambridge Cognition’s tools ensure greater comparability and superior data quality across Actinogen’s clinical development programme.

This collaboration underscores the proven effectiveness of their solutions in critical Alzheimer’s research.